Biotech
News Category
Darwin AG Rebrands as Novogenia AG to Unify Corporate and Brand Identity
Darwin AG has changed its name to Novogenia AG, aligning the parent company with its core operating brand to enhance market visibility and support int...
NanoViricides Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
NanoViricides reports progress toward a Phase II trial of its oral gummies formulation NV-387 for the Bundibugyo ebolavirus outbreak in the DRC, which...
Redwood AI Corp. Joins CSE25 Index, Boosting Visibility Among Growth Investors
Redwood AI Corp. has been added to the CSE25 Index, highlighting its position among the largest companies on the Canadian Securities Exchange and pote...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Major Depressive Disorder on Track
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Quantum BioPharma's Lucid-MS Offers New Hope for Multiple Sclerosis Treatment
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting the limitations of current MS therapies and the potential of its drug candid...
Drug Delivery Innovation Emerges as Key Frontier in Oncology
The article highlights how advanced drug delivery systems, such as Oncotelic Therapeutics' Deciparticle platform, are gaining traction as a cost-effec...
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Quantum BioPharma is progressing its novel MS therapy Lucid-MS to Phase 2 trials after positive Phase 1 results, offering a potential shift from immun...
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Enhancing Precision Cancer Therapy
VERAXA Biotech's new in vitro data validates its BiTAC-ADC platform's ability to selectively kill cancer cells while minimizing toxicity, supporting i...
Redwood AI Corp. Leverages AI to Transform Chemistry R&D Across Multiple Sectors
Redwood AI Corp. uses proprietary AI platforms to accelerate chemistry research and development, with implications for faster drug discovery, defense ...
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for NV-387 Oral Gummies
NanoViricides announced approval from the DRC Pillar Committee to proceed with a Phase II trial of NV-387 Oral Gummies for the Bundibugyo ebolavirus o...
Helus Pharma Chief Medical Officer to Present at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma announced that its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ...
Onco-Innovations Advances Manufacturing Process for Lead Drug Candidate ONC010
Onco-Innovations has initiated process development and scale-up activities for its proprietary drug candidate ONC010, a key step toward IND-enabling s...
Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis After Positive Phase 1 Trial
Quantum BioPharma's LUCID-MS program shows promise in addressing myelin repair and neuroprotection for MS, with a favorable safety profile in phase 1 ...
NeuroOne to Present at Planet MicroCap Las Vegas 2026 Conference
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing commercialization updates and ...
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
GeoVax CEO comments on recent pharmaceutical industry acquisitions that signal a strategic shift toward prioritizing vaccine innovation, health securi...
Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
Quantum BioPharma advances its lead MS drug candidate Lucid-MS and commercial alcohol metabolism product unbuzzd(TM), with an upcoming Phase 2 trial a...
Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Promising Clinical Pipeline
Helus Pharma announced its participation in a fireside chat at the Jefferies Global Healthcare Conference, highlighting its Phase 3 and Phase 2 trials...
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak
NanoViricides announces that its broad-spectrum antiviral candidate NV-387 should be evaluated for treating the Bundibugyo strain Ebola outbreak, give...
SureNano Science Targets GLP-1 Obesity Market with Novel Peptide GEP-44
SureNano Science Ltd. is positioning itself in the booming GLP-1 therapy market by advancing GEP-44, a patented peptide with potential for improved to...
Oncotelic Therapeutics Proves Small Biotech Can Out-Innovate Big Pharma with 28 Million Scientific Abstracts Integrated into AI Platform
Oncotelic Therapeutics integrates 28 million scientific abstracts into its proprietary PDAOAI platform, positioning itself as a key player in the rapi...
Telomir Pharmaceuticals Reports Peer-Reviewed Preclinical Data Supporting Telomir-Zn in Wilson’s Disease
Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data showing that Telomir-Zn improves survival and reduces oxidative st...
Lantern Pharma Receives FDA Support for HARMONIC Trial Amendments in Never-Smoker NSCLC
Lantern Pharma announced FDA clearance on proposed protocol amendments for its Phase 2 HARMONIC trial, clarifying a regulatory path focusing on EGFR e...
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak
NanoViricides emphasizes the potential of its oral drug candidate NV-387 as a pandemic preparedness tool against the current Ebola outbreak, targeting...
Quantum BioPharma Announces Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study
Quantum BioPharma reports that patient enrollment in its collaborative MS imaging study with Massachusetts General Hospital has reached the halfway po...
LIXTE Biotechnology Reports First-Quarter Progress on Lead Candidate and Strategic Expansion
LIXTE Biotechnology advances its oncology pipeline with LB-100 ovarian cancer trial expansion and growth at its Liora Technologies subsidiary, signali...
Dogwood Therapeutics Reports First Quarter 2026 Financial Results and Pipeline Progress
Dogwood Therapeutics announced first quarter 2026 financial results, highlighting strong operational start with significant pipeline progress for Haln...
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Innovations in crossing the blood-brain barrier, such as Oncotelic's intranasal nose-to-brain system, are poised to transform CNS drug delivery and op...
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related neuropsychiatric conditions...
Hantavirus Outbreak on Cruise Ship Raises Concerns About Little-Known Infection
A hantavirus outbreak on the MV Hondius cruise ship has resulted in three fatalities, highlighting the dangers of this rare infection and the importan...
NanoViricides Receives FDA Orphan Drug Designation for NV-387 to Treat Measles Amid Rising Global Outbreaks
NanoViricides' broad-spectrum antiviral NV-387 has been granted Orphan Drug Designation by the FDA for measles, offering regulatory incentives and pos...
VolitionRx Achieves Finger-Prick Breakthrough for Nucleosome Detection in Sepsis, Expanding Point-of-Care Potential
VolitionRx announced a technical milestone in detecting nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototyp...
Helus Pharma Partners With TARA Mind to Boost Veteran Recruitment for Phase 3 Depression Trial
Helus Pharma collaborates with TARA Mind and VETS to enhance veteran recruitment for its Phase 3 trial of HLP003 for major depressive disorder, levera...
Ventripoint's VMS+™ 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.
Ventripoint Diagnostics' AI-powered cardiac imaging system, VMS+™ 4.0, has been submitted for NMPA approval in China under a green pathway, potentiall...
Formycon to Report FY2025 Results and Participate in Major Investor Conferences in Q2 2026
Formycon AG will publish its FY2025 results on April 22, 2026, and management will attend key investor events in Q2 2026, including the Jefferies Glob...
Helus Pharma Appoints Dr. Ken Kramer as SVP of Medical Affairs
Helus Pharma appoints Dr. Ken Kramer, a seasoned neuroscience executive, to lead medical affairs as the company advances its Phase 3 depression treatm...
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
GeoVax is set to initiate a pivotal Phase 3 trial for its mpox/smallpox vaccine GEO-MVA in the second half of 2026, aiming to address global vaccine s...
Kairos Pharma Earns 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
Kairos Pharma receives the 2026 Pinnacle Award for its innovative approach to overcoming cancer drug resistance through its lead candidate ENV-105, hi...
HeartBeam Launches Public Offering to Advance Cardiac AI and Commercialization of FDA-Cleared ECG System
HeartBeam Inc. announced an underwritten public offering to fund commercialization of its FDA-cleared 12-lead synthesized ECG system, AI development, ...
Lixte Biotech Advances Precision Oncology with LB-100, Expands Partnerships
Lixte Biotech Holdings is advancing its lead candidate LB-100, a first-in-class therapy to enhance existing cancer treatments, through expanded clinic...
Lixte Biotech Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
Lixte Biotechnology Holdings Inc. is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance existing cancer treatments, whi...
NanoViricides to Initiate Phase II MPox Trial in DRC, Advancing NV-387 Against Clade I Virus
NanoViricides announced plans to begin a Phase II clinical trial of its antiviral candidate NV-387 for MPox in the Democratic Republic of Congo, evalu...
BioStem Technologies to Present at Prestigious Needham Healthcare Conference, Highlighting Regenerative Medicine Advances
BioStem Technologies will present at the 25th Annual Needham Virtual Healthcare Conference, showcasing its proprietary allograft technologies and expa...
Telomir Pharmaceuticals Submits IND for Telomir-1 in Triple-Negative Breast Cancer
Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for Telomir-1, a novel epigenetic therapy for advanced triple...
Ketryx Launches First Validated AI Conference for Regulated Industries
Ketryx announces its inaugural Validated AI Conference, a first-of-its-kind event uniting professionals building AI in regulated environments to share...
Aemetis CEO Eric McAfee Receives Holmberg Award for Lifetime Achievement in the Bioeconomy
Aemetis CEO Eric McAfee was awarded the 2026 William C. Holmberg Memorial Award for his decades-long contributions to the renewable fuels industry, hi...
Helix BioPharma Faces Cash Crunch After Failed Financing, Pursues New Funding for U.S. Listing
Helix BioPharma Corp. reports a reduced net loss but critically low cash reserves of $31,000, following a failed $33.37 million financing, and is acti...
FDA Orphan Drug Designation for Glafabra’s GT-GLA-S03 Marks Milestone in Redosable Cell Therapy for Fabry Disease
The FDA granted Orphan Drug Designation to GT-GLA-S03, Glafabra Therapeutics’ lead cell therapy for classic Fabry disease, offering market exclusivity...